Table 1.
Demographics of patients with oropharynx cancer treated on TAX 324
| HPV+ (N = 56, 50%), n (%) | HPV− (N = 55, 50%), n (%) | HPV tested (N = 111), n (%) | No HPV status (N = 153), n (%) | P valuea | P valueb | |
| Treatment | ||||||
| TPF | 28 (50) | 26 (47) | 54 (49) | 78 (51) | 0.85 | 0.80 |
| PF | 28 (50) | 29 (53) | 57 (51) | 75 (49) | ||
| Sex | ||||||
| Male | 45 (80) | 44 (80) | 89 (80) | 130 (85) | 1.0 | 0.32 |
| Female | 11 (20) | 11 (20) | 22 (20) | 23 (15) | ||
| Ethnicity | ||||||
| White | 54 (96) | 46 (84) | 100 (90) | 130 (86) | 0.03 | 0.22 |
| Black | 1 (2) | 7 (13) | 8 (7) | 11 (7) | ||
| Other | 1 (2) | 2 (4) | 3 (3) | 12 (8) | ||
| Age (years), median (range) | 54 (39–71) | 58 (41–78) | 55 (39–78) | 55 (38–78) | 0.02 | 1.0 |
| Operability | ||||||
| Unresectable | 14 (25) | 25 (46) | 39 (35) | 65 (42) | 0.04 | 0.005 |
| Low curability | 16 (29) | 16 (29) | 32 (29) | 60 (39) | ||
| Organ preservation | 26 (46) | 14 (26) | 40 (36) | 28 (18) | ||
| Nodal stage | ||||||
| N0–N1 | 13 (23) | 18 (33) | 31 (28) | 39 (25) | 0.30 | 0.67 |
| N2–N3 | 43 (77) | 43 (77) | 80 (72) | 114 (75) | ||
| T stage | ||||||
| T1–T2 | 28 (49) | 11 (20) | 39 (35) | 42 (27) | 0.001 | 0.22 |
| T3–T4 | 28 (51) | 44 (80) | 72 (65) | 110 (72) | ||
| TX | 0 | 0 | 0 | 1 (1) | ||
| Clinical stage | ||||||
| III | 10 (18) | 5 (9) | 15 (14) | 19 (12) | 0.27 | 0.85 |
| IV | 46 (82) | 50 (91) | 96 (86) | 133 (87) | ||
| NA | 1 (1) | |||||
| WHO PS | ||||||
| 0 | 43 (77) | 27 (49) | 70 (63) | 85 (56) | 0.003 | 0.31 |
| 1 | 13 (23) | 28 (51) | 41 (37) | 66 (43) | ||
| NA | 2 (1) |
a
Exact two-sided P value for testing null hypothesis of no difference in parameter’s distribution between HPV+ and HPV− patients.
b
Exact two-sided P value for testing null hypothesis of no difference in parameter’s distribution between patients with HPV status assessed and those without evaluable tissues.
HPV, human papillomavirus; T, tumor; WHO PS, World Health Organization performance status.